More than half of adults with inflammatory bowel disease have at least one psychiatric comorbidity, according to research ...

Abivax shares jump as obefazimod meets key Phase 3 trial endpoints in ulcerative colitis with strong remission rates and a favorable safety profile.

Abivax’s ulcerative colitis drug meets primary goals in Phase 3 trials; shares jump 400% Stock Markets Published 07/23/2025, 07:21 AM 0 ...

Among the 1,275 patients randomized in the induction trials, 678 achieved clinical response and enrolled into part 1 of the maintenance trial. The ABTECT program is one of the largest Phase 3 ...

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative ...

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis ...

My brother-in-law said, ‘You wouldn’t have been able to do this a few years ago.’ It’s changed my life completely.” Her story mirrors findings from a new study by the University of Edinburgh, which ...

Send comments and news tips to [email protected]. Cite this: Does Tofacitinib Worsen Postoperative Complications in Acute Severe Ulcerative Colitis? - Medscape - July 11, 2025.